Guerbet S A : 24/09/2020 - Résultats Semestriels 2020 (Présentation En Anglais)

HY 2020 - HALF-YEAR SALES & RESULTS

SEPTEMBER 24, 2020

Disclaimer

Certain information included in this presentation and other statements or materials published by Guerbet (the "Company") are not historical facts but are forward-looking statements. These forward-looking statements refer in particular to the Company's management's business strategies, its expansion and growth of operations, future

events, trends or objectives and expectations, which are naturally subject to risks and contingencies that may lead to actual results materially differing from those

explicitly or implicitly included in these statements.

Forward-looking statements speak only as of the date of this presentation and, subject to any legal requirement, the Company does not undertake to update or revise the forward-looking statements that may be presented in this document to reflect new information, future events or for any other reason and any opinion expressed in this presentation is subject to change without notice. Such forward looking statements are for illustrative purposes only. Forward-looking information and statements are not guarantees of future performances and are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of the Company. These risks and uncertainties include among other things, the uncertainties inherent in research and development of new products, including future clinical trial results and analysis of clinical data (including post-marketing data), decisions by regulatory authorities, such as the Food and Drug Administration or the European Medicines Agency, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as

their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates. A detailed description of risks

and uncertainties related to the Company's activities is included under Chapter 4.3 "Risk factors" in the Registration Document (Document de Référence) of the Company which has been filed with the French Financial Markets Authority on April 5, 2017 under the number n°D-17-0323 and is available on the Company's website (www.guerbet.com).

This presentation contains statistics, data and other information relating to markets, market sizes, market shares, market growth, market positions and other industry data pertaining to the Company's business and markets. Such information is based on the Company's analysis of multiple internal and third party sources, including information extracted from market research, governmental and other publicly available information, independent industry publications and information and reports. The Company, its affiliates, shareholders, directors, officers, advisors, employees and representatives have not independently verified the accuracy of any such market data and industry forecasts. Such data and forecasts are included in this presentation for information purposes only.

Some of the financial information contained in this presentation is not directly extracted from the Company's accounting systems or records and does not constitute International Financial Reporting Standards (IFRS) accounting measures, including in particular EBITDA. The Company calculates EBITDA as operating income, with the net allowance for amortization, depreciation and provisions added back in. EBITDA is not a measure of financial performance under IFRS and the definition of the term used by the Company may not be comparable to similar terms used by other companies. Such information has not been independently reviewed or verified by the Company's auditors.

This presentation does not contain or constitute an offer of securities for sale or an invitation or inducement to invest in securities in France, the United States or any other jurisdiction.

2	HY 2020 - HALF-YEAR SALES & RESULTS

Welcome

€817 m in 2019

DAVID HALE

Chief Executive Officer

2 820 employees in 2019

€73m dedicated to R&D ; 9% of sales

JÉRÔME ESTAMPES

Chief Financial Officer

Distributed in over 80 countries

3	HY 2020 - HALF-YEAR SALES & RESULTS

Agility & Resilience despite COVID-19 impact

SALES: IMPACT OF COVID

First-half sales down 9.2% (at current rate)

COVID impact varies by regions

MARGIN: COST CONTROL

Strong cost management

Ahead of cost-to-win targets

CASH / INVENTORY / NET DEBT VIGILANCE

Active cash management

Improvement of WCR - acceleration of deleveraging

MAINTAIN STRATEGIC ROADMAP

Development projects running on a normal basis scenario

4 HY 2020 - HALF-YEAR SALES & RESULTS

GUERBET IS READY FOR

ACTIVITY REIGNITION WITH

AN OPTIMIZED COST

STRUCTURE FAVOURING OPERATIONAL MARGIN